Dosimetric feasibility analysis and presentation of an isotoxic dose-escalated radiation therapy concept for glioblastoma used in the PRIDE trial (NOA-28; ARO-2022-12)

Authors:

Abstract
No abstract available
Funding Information
  • Eberhard Karls Universität Tübingen

This publication has 43 references indexed in Scilit: